Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Riedl, 2003, Adverse drug reactions: types and treatment options, Am Fam Physician, 68, 1781

Roujeau, 2005, Clinical heterogeneity of drug hypersensitivity, Toxicology, 209, 123, 10.1016/j.tox.2004.12.022

Wolf, 2005, Life-threatening acute adverse cutaneous drug reactions, Clin Dermatol, 23, 171, 10.1016/j.clindermatol.2004.06.012

Roujeau, 1994, Severe cutaneous adverse reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906

Chan, 1990, The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients, Arch Dermatol, 126, 43, 10.1001/archderm.1990.01670250049006

Roujeau, 1990, Toxic epidermal necrolysis (Lyell syndrome), J Am Acad Dermatol, 23, 1039, 10.1016/0190-9622(90)70333-D

Schopf, 1991, Toxic epidermal necrolysis and Stevens–Johnson syndrome. An epidemiologic study from West Germany, Arch Dermatol, 127, 839, 10.1001/archderm.1991.01680050083008

Chohan, 2009, Update on emerging urate-lowering therapies, Curr Opin Rheumatol, 21, 143, 10.1097/BOR.0b013e328325bd94

Halevy, 2008, Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel, J Am Acad Dermatol, 58, 25, 10.1016/j.jaad.2007.08.036

Lin, 2005, Risk estimates for drugs suspected of being associated with Stevens–Johnson syndrome and toxic epidermal necrolysis: a case-control study, Intern Med J, 35, 188, 10.1111/j.1445-5994.2005.00790.x

Lee, 2008, Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?, Singapore Med, 49, 384

Jantararoungtong, 2009, Stevens–Johnson syndrome and toxic epidermal necrolysis in Srinagarind hospital: a retrospective study of causative drugs and clinical outcome, Thai J Pharmacol, 31, 41

Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci U S A, 102, 4134, 10.1073/pnas.0409500102

Lonjou, 2008, A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharmacogenet Genomics, 18, 99, 10.1097/FPC.0b013e3282f3ef9c

Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617

Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a

Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenet Genomics, 16, 297, 10.1097/01.fpc.0000199500.46842.4a

Locharernkul, 2008, Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population, Epilepsia, 49, 2087, 10.1111/j.1528-1167.2008.01719.x

Lonjou, 2006, A marker for Stevens–Johnson syndrome: ethnicity matters, Pharmacogenomics J, 6, 265, 10.1038/sj.tpj.6500356

Hurley, 2003, Immunobiology of the human MHC, 337

Haldane, 1956, The estimation and significance of the logarithm of a ratio of frequencies, Ann Hum Genet, 20, 309, 10.1111/j.1469-1809.1955.tb01285.x

Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet, 359, 1121, 10.1016/S0140-6736(02)08158-8

Dainichi, 2007, Stevens–Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?, Dermatology, 215, 86, 10.1159/000102045